Skip to main content

Drug Interactions between duloxetine and tryptophan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

tryptophan DULoxetine

Applies to: tryptophan and duloxetine

GENERALLY AVOID: Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 5-HT2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.

MANAGEMENT: In general, the concomitant use of tryptophan and agents with serotonergic activity such as serotonin reuptake inhibitors should be avoided. If concomitant use is considered clinically necessary, caution and close monitoring for signs and symptoms of serotonin syndrome is recommended, particularly at treatment initiation and during any dosage increases. Patients should be instructed to seek immediate medical attention if they develop any signs or symptoms of serotonin syndrome. The product labeling for each serotonergic medication as well as any relevant guidelines should also be consulted for specific recommendations.

References (17)
  1. (2001) "Product Information. Zoloft (sertraline)." Roerig Division
  2. (2001) "Product Information. Prozac (fluoxetine)." Dista Products Company
  3. (2001) "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Paxil (paroxetine)." GlaxoSmithKline
  5. (2001) "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc
  6. (2001) "Product Information. Celexa (citalopram)." Forest Pharmaceuticals
  7. (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company
  8. (2008) "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories
  9. (2009) "Product Information. Savella (milnacipran)." Forest Pharmaceuticals
  10. (2009) "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals
  11. (2011) "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC
  12. (2013) "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals
  13. (2013) "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America
  14. (2023) "Product Information. Escitalopram (Apo) (escitalopram)." Arrotex Pharmaceuticals Pty Ltd
  15. (2024) "Product Information. Escitalopram (escitalopram)." Milpharm Ltd
  16. (2024) "Product Information. Escitalopram Oxalate (escitalopram)." Aurobindo Pharma USA Inc
  17. (2024) "Product Information. ACH-Escitalopram (escitalopram)." Accord Healthcare

Drug and food interactions

Moderate

DULoxetine food

Applies to: duloxetine

GENERALLY AVOID: Use of duloxetine in conjunction with chronic alcohol consumption may potentiate the risk of liver injury. Duloxetine alone can increase serum transaminase levels. In clinical trials, 0.3% of patients discontinued duloxetine due to liver transaminase elevations. The median time to detection was about two months. Three duloxetine-treated patients had liver injury as manifested by transaminase and bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, which may have contributed to the abnormalities observed. Duloxetine does not appear to enhance the central nervous system effects of alcohol. When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol.

MANAGEMENT: Due to the risk of liver injury, patients prescribed duloxetine should be counseled to avoid excessive use of alcohol. Duloxetine should generally not be prescribed to patients with substantial alcohol use.

References (1)
  1. (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.